ArticleJCO global oncology2020

Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma.

Jeronimo Rafael Rodríguez-Cid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.